ArticleFrontiers in genetics2025
Expression characteristics, molecular mechanisms, and clinical significance of DICER1 in breast cancer.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the expression patterns, molecular mechanisms, and clinical significance of DICER1 in breast cancer (BRCA), providing new biomarkers and therapeutic targets for prognosis assessment and personalized treatment of breast cancer. Methods: By integrating RNA-seq data, clinical data, and tumor mutation burden (TMB) data from The Cancer Genome Atlas (TCGA) database, as well as single-cell transcriptomic data from the Gene Expression Omnibus (GEO) database, we analyzed the expression characteristics of DICER1 in breast cancer. Weighted gene co-expression network analysis (WGCNA) was used to identify gene modules associated with the breast cancer phenotype, and gene set enrichment analysis (GSEA) was performed to explore their biological functions. Cellular experiments were conducted to verify the effects of DICER1 on the proliferation, migration, and invasion of breast cancer cells. A nomogram model was constructed based on clinical data to evaluate its prognostic value. Additionally, the effects of DICER1 expression levels on drug sensitivity and the tumor immune microenvironment were analyzed. Results: The expression of DICER1 in breast cancer tissues was significantly lower than that in normal tissues, and was significantly correlated with tumor stage, T stage, and TMB levels. The expression level of DICER1 was an independent prognostic factor for breast cancer patients. The nomogram model based on DICER1 expression and clinical features demonstrated good discriminative ability in predicting patient survival probability. Drug sensitivity analysis revealed that the high-expression group of DICER1 exhibited higher sensitivity to multiple drugs. Immune microenvironment analysis indicated that the low-expression group of DICER1 had higher immune-suppressive features and immune exclusion scores, suggesting potential resistance to immunotherapy. Single-cell transcriptomic analysis revealed heterogeneous expression of DICER1 in breast cancer cell populations and its potential role in cell-cell communication. Conclusion: DICER1 plays an important regulatory role in breast cancer, with its expression level closely related to tumor progression, the immune microenvironment, and drug sensitivity. DICER1 has the potential to become an important biomarker for prognosis assessment in breast cancer and may provide new targets for future immunotherapy and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.